Triazinone compound and t-type calcium channel inhibitor

Disclosed herein are triazinone compounds of formula I where the substituents are as defined herein or a tautomer or a pharmaceutically acceptable salt of the compound. The compounds have an inhibitory activity on a T-type voltage-dependent calcium channel and are useful particularly for the treatme...

Full description

Saved in:
Bibliographic Details
Main Authors KAWAZU TAKESHI, SHINTANI YUSUKE, INABA YUSUKE, ADACHI MICHIAKI, HIRAI YUICHI, YASUTAKE KOICHI, NAGAI HIROSHI, UENO MEGUMI, EGI JUN, TAKAHASHI DAIKI, SAITO NORIKO
Format Patent
LanguageEnglish
Published 29.04.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract Disclosed herein are triazinone compounds of formula I where the substituents are as defined herein or a tautomer or a pharmaceutically acceptable salt of the compound. The compounds have an inhibitory activity on a T-type voltage-dependent calcium channel and are useful particularly for the treatment of pain. Also disclosed are therapeutic agents and medicines comprising the compounds.
AbstractList Disclosed herein are triazinone compounds of formula I where the substituents are as defined herein or a tautomer or a pharmaceutically acceptable salt of the compound. The compounds have an inhibitory activity on a T-type voltage-dependent calcium channel and are useful particularly for the treatment of pain. Also disclosed are therapeutic agents and medicines comprising the compounds.
Author EGI JUN
ADACHI MICHIAKI
INABA YUSUKE
YASUTAKE KOICHI
UENO MEGUMI
SHINTANI YUSUKE
TAKAHASHI DAIKI
SAITO NORIKO
NAGAI HIROSHI
HIRAI YUICHI
KAWAZU TAKESHI
Author_xml – fullname: KAWAZU TAKESHI
– fullname: SHINTANI YUSUKE
– fullname: INABA YUSUKE
– fullname: ADACHI MICHIAKI
– fullname: HIRAI YUICHI
– fullname: YASUTAKE KOICHI
– fullname: NAGAI HIROSHI
– fullname: UENO MEGUMI
– fullname: EGI JUN
– fullname: TAKAHASHI DAIKI
– fullname: SAITO NORIKO
BookMark eNrjYmDJy89L5WSwCCnKTKzKBHEUkvNzC_JL81IUEoG4RLeksgAolpiTnFmaq5CckZiXl5qjkJmXkZmUWZJfxMPAmpaYU5zKC6W5GeTcXEOcPXRTC_LjU4sLEpNT81JL4v2izIzMDA2NHI0JKgAAFFMvJg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID NZ626112A
GroupedDBID EVB
ID FETCH-epo_espacenet_NZ626112A3
IEDL.DBID EVB
IngestDate Fri Jul 19 15:12:13 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_NZ626112A3
Notes Application Number: NZ20130626112
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160429&DB=EPODOC&CC=NZ&NR=626112A
ParticipantIDs epo_espacenet_NZ626112A
PublicationCentury 2000
PublicationDate 20160429
PublicationDateYYYYMMDD 2016-04-29
PublicationDate_xml – month: 04
  year: 2016
  text: 20160429
  day: 29
PublicationDecade 2010
PublicationYear 2016
RelatedCompanies NISSAN CHEMICAL INDUSTRIES LTD
RelatedCompanies_xml – name: NISSAN CHEMICAL INDUSTRIES LTD
Score 3.0394847
Snippet Disclosed herein are triazinone compounds of formula I where the substituents are as defined herein or a tautomer or a pharmaceutically acceptable salt of the...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Triazinone compound and t-type calcium channel inhibitor
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160429&DB=EPODOC&locale=&CC=NZ&NR=626112A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dS8MwED_mFPVN5_fHyIP0rditabs8FHH9YAjrhkwZexnNTLWgdWwdgn-9d6FTX_YQCAkcyZH7SnK_A7jhNu_YaCZMwb0MAxRhmdISnsm5QOuSCu5oiI1-4vae-MPYGdfgdZ0Lo3FCvzQ4IkrUDOW91Pp6_neJFeq_lctbmePQ51088kOjio5bLulXI-z60XAQDgIjCPxkYiSPPvrt6Fncb8E2-dAEsh89dyklZf7fnsQHsDNEUkV5CDVVNGAvWJdda8Buv3rtxm4leMsj6IzwoHznGKsrRr_AqRgSS7GVJl2iMuT0LF99MMrjLdQ7y4u3XKKwLo6hGUejoGfiEqa_m50mk2qp9gnUieoZMJUqZaXtzHVVxqWTSs9yXmyCUlEt23G9czjdQORi48wl7BO_6GGkLa6gXi5W6hrtaymbmjc_AEd_nQ
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NS8MwFH_MKc6bzu-PmYP0VuzWtF0ORVy7UnXthlQZu5RmplrQOrYOwb_el9Kplx0CIYFH8sj7SvJ-D-CK6rSro5lQGbVSDFCYpnKNWSqlDK1LwqhRQmwEoek_0fuxMa7B6yoXpsQJ_SrBEVGipijvRamvZ3-XWG75t3JxzTMc-rzxIttVqui4bUr9qrg9uz8aukNHcRw7nCjho41-O3oWtxuwaUloXuk3PfdkSsrsvz3xdmFrhKTyYg9qIm9Cw1mVXWvCdlC9dmO3ErzFPnQjPCjfGcbqgshf4LIYEkmwFaq8RCXI6Wm2_CAyjzcX7yTL3zKOwjo_gJbXjxxfxSXEv5uNw0m1VP0Q6pLqMRCRCKElndQ0RUq5kXBLM150CaUi2rphWidwtIbI6dqZS2j4UTCIB3fhwxnsSN7JR5IOO4d6MV-KC7S1BW-VfPoBIAaCig
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Triazinone+compound+and+t-type+calcium+channel+inhibitor&rft.inventor=KAWAZU+TAKESHI&rft.inventor=SHINTANI+YUSUKE&rft.inventor=INABA+YUSUKE&rft.inventor=ADACHI+MICHIAKI&rft.inventor=HIRAI+YUICHI&rft.inventor=YASUTAKE+KOICHI&rft.inventor=NAGAI+HIROSHI&rft.inventor=UENO+MEGUMI&rft.inventor=EGI+JUN&rft.inventor=TAKAHASHI+DAIKI&rft.inventor=SAITO+NORIKO&rft.date=2016-04-29&rft.externalDBID=A&rft.externalDocID=NZ626112A